RedHill Biopharma Free Cash Flow (FCF) History (RDHL)

RedHill Biopharma reported −$9.4M in free cash flow for fiscal 2024, an increase of $26.5M from the previous fiscal year, with a free cash flow margin of −116.60%.

View full RedHill Biopharma company overview

RedHill Biopharma free cash flow by year

RedHill Biopharma annual free cash flow

Fiscal yearPeriod endedFree cash flowChangeGrowthFCF margin
20242024-12-31−$9.4M$26.5M−116.60%
20232023-12-31−$35.8M−$6.4M−548.71%
20222022-12-31−$29.4M$35.8M−47.55%
20212021-12-31−$65.2M−$16.2M−75.98%
20202020-12-31−$49.0M−$8.1M−76.11%
20192019-12-31−$40.9M−$6.4M−650.41%
20182018-12-31−$34.5M$10.4M−412.50%
20172017-12-31−$44.9M−$16.6M−1120.91%
20162016-12-31−$28.3M−$10.5M−28062.38%
20152015-12-31−$17.8M−594666.67%

RedHill Biopharma free cash flow growth trends

Over the last five reported fiscal years, free cash flow grew from −$40.9M to −$9.4M, a net increase of $31.5M. RedHill Biopharma's latest reported quarter, Q2 2022, generated −$16.7M in free cash flow, a decrease of $8.3M year over year.

About the metric

What free cash flow means

Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.

Calculation and source

How free cash flow is calculated

TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.

Review RedHill Biopharma filings at SEC.gov ↗